- L-(+)-Penicillamine
-
- $0.00 / 25KG
-
2024-03-28
- CAS:52-66-4
- Min. Order: 25KG
- Purity: 98%
- Supply Ability: Inquiry
- DL-PENICILLAMINE
-
- $1.00 / 1KG
-
2020-02-05
- CAS:52-66-4
- Min. Order: 1KG
- Purity: 98-99.9%
- Supply Ability: 100kg
|
| DL-PENICILLAMINE Chemical Properties |
Melting point | 204-208 °C(lit.) | Boiling point | 251.8±35.0℃ (760 Torr) | density | 1.204±0.06 g/cm3 (20 ºC 760 Torr) | refractive index | 1.5216 (estimate) | Fp | 106.1±25.9℃ | storage temp. | Keep in dark place,Sealed in dry,2-8°C | solubility | Methanol (Slightly), Water (Soluble) | pka | pK: 1.8 (carboxyl); 7.9 (a-amino); 10.5 (b-thiol) | form | solid | Water Solubility | Soluble in ethanol, hot water and sodium hydroxide. | Merck | 14,7088 | BRN | 2039817 | CAS DataBase Reference | 52-66-4(CAS DataBase Reference) |
Hazard Codes | Xn | Risk Statements | 22-36/37/38-40-20/21/22 | Safety Statements | 26-36-22 | WGK Germany | 3 | RTECS | YV9445000 | HS Code | 29309099 | Toxicity | LD50 orally in rats: 365 mg/kg (Jaffe) |
| DL-PENICILLAMINE Usage And Synthesis |
Application in Rheumatic Arthritis | Penicillamine onset may be seen in 1 to 3 months, and most responses occur within 6 months. Early adverse effects include skin rash, metallic taste, hypogeusia, stomatitis, anorexia, nausea, vomiting, and dyspepsia. Glomerulonephritis may occur, which manifests as proteinuria and hematuria. Penicillamine is usually reserved for patients who are resistant to other therapies because of the rare but potentially serious induction of autoimmune diseases (e.g., Goodpasture’s syndrome, myasthenia gravis).
| Chemical Properties | white to almost white crystalline powder | Uses | antirheumatic,
chelating agent (copper),
Wilson's desease treatment | Uses | DL-Penicillamine is a penicillin metabolite used in the treatment of Wilson’s disease, Cystinuria, Scleroderma and arsenic poisoning. | Definition | ChEBI: An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group. | Safety Profile | Poison by ingestion and intraperitoneal routes. Mutation data reported. When heated to decomposition it emits toxic fumes of SOx and NOx. |
| DL-PENICILLAMINE Preparation Products And Raw materials |
|